Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martijn Ruppert

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scalesMartijn van Noort, Martijn Ruppert
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model developmentMartijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.
Diabetes, Obesity & Metabolism|December 1, 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKDThomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scalesMartijn van Noort, Martijn Ruppert
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model developmentMartijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.
Diabetes, Obesity & Metabolism|December 1, 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKDThomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, et al.
Pageof 1